scispace - formally typeset
L

Louise Goodwin

Researcher at AstraZeneca

Publications -  8
Citations -  999

Louise Goodwin is an academic researcher from AstraZeneca. The author has contributed to research in topics: Cancer cell & ASK1. The author has an hindex of 8, co-authored 8 publications receiving 766 citations.

Papers
More filters
Journal ArticleDOI

Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation.

TL;DR: Progress using fragment-based lead generation (FBLG), assisted by X-ray crystallography to develop small molecule LDHA inhibitors, which were identified through NMR and SPR screening and optimized into lead compounds with nanomolar binding affinities via fragment linking.
Journal ArticleDOI

Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival

TL;DR: It is concluded that the role of MTH1 in carcinogenesis and utility of its inhibition is yet to be established and the difference between the responses of the highly selective inhibitors and published tool compounds suggests that the effect reported for the latter may be due to off-target cytotoxic effects.
Journal ArticleDOI

Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome

TL;DR: It is demonstrated that DYRK1B also undergoes trans-autophosphorylation on serine-421 (S421) in vitro and in cells and that this site contributes to DYRk1B kinase activity, uncovering new links between two kinases involved in cell fate decisions.